AbbVie Inc. is among the top dividend stocks in healthcare, reaffirmed by Cantor Fitzgerald with an Overweight rating and $250 price target. The firm revised its earnings model to include a $1.50 per share after-tax impact from an In-Process Research and Development charge, lowering Q3 2025 EPS estimate to $1.82. Cantor also raised the expected tax rate for the quarter to around 25%. The company has achieved 53 consecutive years of dividend growth, with a quarterly dividend of $1.64 per share and a yield of 2.86%.

Read more at Yahoo Finance: Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)